The urinary excretion and pharmacokinetics of acrolein (ACRO) and its parent drug cyclophosphamide (CP) were investigated in 16 randomly selected bone marrow transplant (BMT) recipients when CP was used for conditioning. Patients suffering from aplastic anemia (n = 3) received a 4-day course of CP at a dose of 50 mg/kg daily infused intravenously (i.v.) over 1 h. Patients with leukemia (n = 13) were given either a combination of busulphan followed by CP at a dose of 50 mg/kg infused i.v. over 1 h for 4 days, or CP at a dose of 60 mg/kg by i.v. infusion over 1 h daily for 2 days followed by total body irradiation. Serial plasma samples and urine were collected after the start of the first CP dose. CP was analyzed by capillary gas chromatography, whereas ACRO was measured in urine by Cyclophosphamide (CP) is an alkylating agent which requires metabolic activation to exhibit its antineoplastic and immunomodulating activities. Some of the metabolites formed are thought to cross-link with cellular DNA and thereby interfere with proliferation and ultimately lead to cell death. In bone marrow transplantation (BMT), CP is currently playing a major role as part of conditioning regimens. This treatment allows acceptance of the graft in allogenic BMT and serves in allo-as well as autologous BMT to eradicate malignant cells or create space in the marrow cavity. CP undergoes complicated metabolism involving several pathways in vivo.
Cyclophosphamide (CP) is an alkylating agent which requires metabolic activation to exhibit its antineoplastic and immunomodulating activities. Some of the metabolites formed are thought to cross-link with cellular DNA and thereby interfere with proliferation and ultimately lead to cell death. In bone marrow transplantation (BMT), CP is currently playing a major role as part of conditioning regimens. This treatment allows acceptance of the graft in allogenic BMT and serves in allo-as well as autologous BMT to eradicate malignant cells or create space in the marrow cavity. CP undergoes complicated metabolism involving several pathways in vivo. 1 The main pathway involves hydroxylation of CP by hepatic microsomal oxidases to form 4-hydroxy-cyclophosphamide (4OH-CP) which is in equilibrium with its acyclic tautomeric form, aldophosphamide (ALDO). These metabolites are transport forms of CP. Oxidation of ALDO by aldehyde dehydrogenase results in the noncytotoxic metabolite carboxyphosphamide. Dehydrogenation of 4OH-CP gives another inactive metabolite, 4-keto cyclophosphamide. The final stage of activation, which takes place in cells that are susceptible, involves cleavage of 4OH-CP/ALDO by a ␤-elimination reaction to yield phosphoramide mustard and ACRO both of which are highly cytotoxic and represent active forms of the drug. One of the major dose-limiting side-effects of CP is hemorrhagic cystitis (HC) 2 which has been attributed to the urinary excretion of its metabolites, particularly ACRO. [3] [4] [5] Hemorrhagic cystitis which occurs in a somewhat unpredictable way, may be the result of altered pharmacokinetics of CP or elevated formation and/or variation in the renal excretion of ACRO. It may also be ascribed to inadequate urinary concentration of mesna, 5 a uroprotective agent used for neutralizing the damaging effect of ACRO by chelation.
This study was undertaken to investigate the urinary excretion and pharmacokinetics of ACRO and its parent drug CP in BMT recipients when CP is used for conditioning, and to examine the relationship between hemorrhagic cystitis and urinary excretion of ACRO.
Patients and methods

Patient selection
A total of 16 patients ranging in age between 14 and 46 years were randomly selected among the BMT recipients. Prior to entry into the study all patients gave their written informed consent in accordance with the Helsinki Declaration. This investigation was approved by the Research Ethics Committee in this institution. The patients comprised seven females and nine males who had acute lymphoblastic leukemia (ALL; five patients), acute myeloid leukemia (AML; three patients), chronic myelocytic leukemia (CML; five patients), aplastic anemia (AA; three patients).
Treatment
The clinical protocol used by the BMT Unit at King Faisal Specialist Hospital and Research Centre for these patients was followed strictly. All patients received intensive hydration to ensure good urine production. Intravenous fluid was started 9 h before CP and continued until 24-48 h after the last dose of CP at an infusion rate of 200 ml/h. All patients received mesna, for uroprotection, given as a loading dose of 30 mg/kg 15 min before each dose of CP followed by a continuous i.v. infusion for 12 h after CP infusion at a dose of 100 mg/kg. Additionally, a loop diuretic (furosemide/frusemide) was given at the discretion of the treating physician to achieve adequate urine output and maintain fluid balance.
Cyclophosphamide was administered depending on the type of disease treated. Patients suffering from aplastic anemia received a 4-day course of intravenous CP at a dose of 50 mg/kg daily infused over 1 h. Patients with leukemia were given either a combination of busulphan (administered at a dose of 16 mg/kg delivered over 4 days) followed by CP at a dose of 50 mg/kg infused i.v. over 1 h for 4 days, or CP at a dose of 60 mg/kg by i.v. infusion over 1 h daily for 2 days followed by total body irradiation at a dose of 12 GY given over 3 days in six fractions.
Blood and urine collection
Blood samples (3.3 ml) were collected in heparinized tubes at the following sampling times: 0.25, 0.5, 1, 1.5, 2, 3, 6, 9, 12, 18, 20, and 24 h after the initiation of CP infusion. The samples were immediately centrifuged at 1100 g and 4°C, and the plasma was harvested and stored instantly at −80°C until analysis.
The patient was asked to empty the bladder just before the start of CP infusion. Urine from six patients was then collected at 4-h intervals in a plastic container containing 2 g of sodium metabisulfite as antioxidant, for a total of six fractions. As this multiple fraction urine collection proved to be difficult to handle clinically, urine from the 10 remaining patients was collected over a 24-h interval in a similar container which was kept at 4°C for the duration of the collection. With both approaches, the volume collected in each interval was measured and a 10-ml aliquot was stored at −80°C until analysis.
Analysis of cyclophosphamide and acrolein in study samples
Cyclophosphamide was analyzed in plasma and urine by capillary gas chromatography according to the procedure described by El-Yazigi and Martin. 6 The linearity of the assay for both plasma and urine was good with correlation coefficient (r) Ͻ 0.991 (range 0.991-0.9999; mean 0.9963). The intra-run precision was equally good with coefficient of variation (CV) at different concentrations in plasma or urine of Ͻ3.4%.
Acrolein was measured in urine after derivatization with m-aminophenol by high performance liquid chromatography according to the method of Al-Rawithi et al. 7 The linearity of the assay was good with (r) Ͼ 0.994 (range 0.9941-0.999; mean 0.9964). The intra-and inter-run precision was equally good with CV at different concentrations in urine of Ͻ7.9%.
Pharmacokinetic calculations
The plasma concentrations of CP (C) vs time (t) data obtained for each patient were subjected to a non-linear regression analysis according to a two-compartment open model 8 with constant-rate intravenous infusion using the Model-PK personal computer package (McPherson Scientific, Rosanna, Victoria, Australia). The values of the apparent rate constants for the distributive phase (␣), post-distributive phase (␤), transfer of drug from the central compartment to the peripheral compartment (k 12 ), rate constant for transfer of drug from the peripheral compartment to the central compartment (k 21 ), rate constant for elimination of drug from the central compartment (k 10 ), areaunder-the-curve from 0 → ϱ (AUC), mean residence time (MRT), total clearance (CL), and volume of distribution of the central compartment (V c ), at beta-phase (V t ), and at steady-state (V ss ) were computed by the package at the end of each run. The rate of excretion of ACRO or CP in urine (ExR) was calculated by dividing the amount excreted of either compounds during the collection interval (⌬ A u ) (ie, 4 or 24 h) by the length of interval (⌬ t). The fraction of the administered dose of CP excreted in urine as ACRO (f mu ) or in the unchanged form (f u ) was calculated by dividing the amount of ACRO (A mu ) or the unmetabolized CP (A u ) excreted in urine in 24 h by the dose (D), assuming a complete excretion. The normalized urinary concentration of ACRO (C mu(n) ) or CP [C u(n) ] in each fraction collected was calculated by dividing the concentration of ACRO (C mu ) or CP (C u ) in urine by the concentration of creatinine in the same sample (C ucreat ). Normalization of the urinary concentration of ACRO or CP is necessary to eliminate the impact of the difference in urinary output or hydration state among patients when the urinary concentration is to be reported as a separate parameter. It should be noted that creatinine was analyzed in urine using a Jaffe-based reaction (Boehringer Mannheim Automated Analysis for BM Hitachi Systems 747/737; Indianapolis, IN, USA) on a Hitachi 737 analyzer. Also, in all the above calculations the amount of ACRO excreted was converted to its equivalent of the parent drug CP.
Statistical analysis
Data were analyzed with the STATGRAPHICS Statistical Graphic System package (Statistical Graphics, Rockville, MD, USA), and various statistical parameters were calculated. The pharmacokinetic parameters obtained for each of the patients who developed HC were compared to those obtained for patients who did not develop HC using the MNR test. 9 A value of MNR Ͼ 0.681 was equivalent to P р 0.05 and MNR Ͼ 0.75 indicates P р 0.01. The difference was considered significant if the level of significance (P) р 0.05. Table 1 presents the clinical characteristics of the patients. Among the 16 patients included, two developed HC. The diagnosis of HC was based on established criteria. 10 The mean (s.e.m.) values of the serum concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), bilirubin (BIL), total protein (TP), creatinine (SCr), and blood urea nitrogen (BUN) for all the patients were 20.93 (3.54) U/l, 30.6 (7.55) U/l, 87.53 (13.4) U/l, 9.07 (2.76) mol/l, 62.2 (2.05) g/l, 67.81 (5.58) mol/l, and 4.16 (0.41) mmol/l, respectively. Table 2 presents urinary data for ACRO and its parent drug CP in each of the patients included. Table 3 lists the pharmacokinetic parameters obtained from fitting the data for each patient to the two-compartment model. It should be noted that the data fitted this model very well with small and randomly distributed sum of square of observed minus predicted residuals (SSR) around the line. Indeed, the correlation coefficient (r) for six patients exceeded 0.9994. The data were also fitted to the three-compartment model. However, the fit was not as good or at best similar (ie the Akaike and Schwartz Criteria 11 values were larger or similar) to that observed with the less-complicated two-compartment model. Therefore, the latter was adopted.
Results
Realizing that the values of the urinary pharmacokinetic parameters obtained for each of patients Nos 15 and 16 were markedly larger (up to 16-fold) than those observed ANC = absolute neutrophil count; ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; AA = aplastic anemia; CML = chronic myeloid leukemia.
for the remaining patients ( Table 2 ), and that those two patients developed HC, we examined the relationship between HC and the urinary pharmacokinetics of ACRO and CP by comparing the data obtained for each of these two patients with those of the remaining patients who did not develop HC using the maximum normal residual (MNR) test. As shown in Figure 1 , each of the two patients who developed HC significantly (P Ͻ 0.01) excreted more ACRO in the first and second 4-h periods than did the four patients who did not develop HC (NHC) and from whom urine was collected in multiple 4-h fractions. Similarly, while there was no significant difference in any of the plasma pharmacokinetic parameters for CP between either of these patients and those who did not develop HC, the values of A u (P Ͻ 0.01 for either patient), ExR (P Ͻ 0.01 for either patient), and C u(n) (P Ͻ 0.01 for patient No. 15 and P Ͻ 0.05 for patient No. 16) of CP were significantly larger. When the excretion rate (ExR) of CP observed during each 4-h interval for the six patients from whom urine was collected in multiple fractions was compared (Figure 1 ), it was found that the difference was significant only in ExR 0-4h (P Ͻ 0.01 for either patient), ExR 4 
Discussion
The urinary excretion and pharmacokinetics of ACRO following the administration of CP in patients has not been investigated, presumably due to the lack of an analytical method for this compound in biological fluids. Recently, an expedient and accurate liquid chromatographic procedure for analyzing ACRO in urine 7 has been developed. The data obtained in this study indicate that the elimination A u = fraction of CP dose excreted unchanged in 24 h; Cl R = renal clearance of CP; f u = fraction of dose excreted unchanged in 24 h; C u(n) = urinary concentration ratio of CP/creatinine (Cr); ExR = rate of excretion of ACRO in urine over 24 h; C mu(n) = urinary concentration ratio of ACRO/creatinine; f mu = fraction of CP dose excreted in 24-h urine as ACRO.
Table 3
Plasma pharmacokinetic parameters for CP in the patients ␣ and ␤ = apparent rate constants for distribution and post-distributive phases; AUC = area under curve 0-24 h; V c = volume of distribution of central compartment; CL = total body clearance; k 12 = apparent rate constant of drug transfer from central → peripheral compartment; V t = total volume of distribution; k 21 = apparent rate constant of drug transfer from peripheral → central compartment; V ss , steady-state volume of distribution; k 10 = apparent rate constant of drug elimination from central compartment; MRT = mean residence time.
of CP by biotransformation into ACRO is quite limited since only 1.96% of this drug is excreted in 24-h urine as ACRO. This value is much smaller than that recently reported by Chan et al 12 for the percentage of cyclophosphamide excreted in 24-h (f mu ) urine of similar patients as phosphoramide mustard (ie 39.0%), but larger than the f mu reported by the same authors for 4-OH cyclophosphamide (ie 0.5%) and aldphosphamide (ie 0.4%). Unfortunately, ACRO was not addressed by these authors. It is of interest to note that the concentrations of ACRO we found in plasma were exceedingly small and sporadic, which did not permit pharmacokinetic calculations.
The pharmacokinetics of CP have been adequately examined. However, the doses of CP employed in most of the previous reports are markedly smaller than those used for conditioning prior to BMT. It is only recently that more interest has been placed on the pharmacokinetics of CP in high-dose therapy. 13, 14 While the ␤-phase half-life (t 1/2␤ ) of CP obtained in this study is consistent with values reported previously, [15] [16] [17] [18] [19] the value of the ␤-phase volume of distribution (V t ) in this study was somewhat larger than those previously reported for the volume of distribution in humans, 20 which resulted in a markedly larger total clearance (CL) of CP as compared to that reported by other investigators. 16, 19, 21 It should be noted that when a similarly higher dose of CP was used, the volume of distribution at steady state (V ss ) (ie, 30.20 l) 12 was somewhat close to the value of V ss calculated in this study (ie 39.23 l). The mean fraction of CP dose excreted in urine (f u ) in the unchanged form was 14.05% which compares favorably with previously reported values for this parameter (ie 10.78%, 12 17%
13 ) after intravenous infusion of high doses of CP, but a large variation has been observed by other investigators 22 which is also the case in the present study.
Compared to the patients who did not develop HC, patient No. 15 and patient No. 16 who developed HC excreted significantly more ACRO and CP in urine, and the excess in excretion of these compounds occurred mainly during the first 8 h after initiation of CP administration. This concurs with the report of Fraiser 23 who examined CP metabolism and bladder toxicity in mice and concluded that among the factors that affect the differential sensitivity in mice is the velocity of excretion of toxic metabolites (acrolein) into the urine. It is of interest to note that both of the patients who developed HC had the shortest t 1/2␣ while the t 1/2␤ was unaffected, which may explain the urinary excretion pattern of CP in these two patients. Since CP in the unmetabolized form is inert, the toxicity must be related to ACRO. The reason why CP as well as ACRO are excreted to that extent in the urine is unknown. We examined whether the patients differed in any respect (hydration status, previous chemotherapy, concomitant medication) but found no correlation. Probably the phenomenon is related to the high interpatient variability in metabolizing CP. 22 Also, what role mesna played as a uroprotective agent in these patients is unknown. However, in a study we conducted previously on the urinary pharmacokinetics of mesna and dimesna in a similar group of patients, 24 we found that the pharmacokinetics of mesna in patients who developed HC did not differ from that observed in those who did not develop HC, and that the urinary concentration of mesna in all patients was higher than that required for uroprotection. Further, we found that although a significantly smaller amount of dimesna was excreted in urine by patients who developed HC, it appeared that this decrease was the result of nephrotoxic effects of high-dose CP on the renal system, and not the cause of it, since dimesna has no active role in the detoxification of oxazaphosphorine, and its formation from mesna in these patients was found to be unaffected. Thus, it might be difficult to increase uroprotection by means of increased mesna and/or more intensive hydration, an assumption that may have some support in the debate on the relative merits of mesna, hydration, and bladder irrigation. [25] [26] [27] It should be noted, however, that forced hydration may result in a reduced urinary concentration of mesna available for chelation of ACRO, and thus, producing the opposite to the desired effect.
Interestingly, in spite of the great variation in metabolism (two patients excreted 40% of CP in the unmetabolized form) no patient in the present study had graft failure. We used either 200 or 120 mg per kg BW of CP as immunosuppressant and in the case of 120 mg CP the patients received heavy immunosuppression with total body irradiation. A less immunosuppressive regimen combines 120 mg CP with busulphan. 28 In patients with high excretion of unmetabolized CP the conditioning regimen may be inadequate to allow acceptance of the graft. However, in three published studies comparing CP and busulphan vs total body irradiation + CP in adult leukemia no significant difference in graft failure was noticed. [29] [30] [31] In pediatric patients where the highest excretion of unmetabolized CP has been seen, this point may be more valid. 22 In the present study, a strong correlation between peak urinary concentration of CP and ACRO and risk of developing hemorrhagic cystitis was noticed. Until a predictive test for renal excretion of CP and ACRO has been developed, which may be difficult as even intrapatient variability of metabolism of CP has been reported, 32 it seems prudent to administer high-dose CP over a longer period of time to avoid high peak concentration of drug and metabolite in the urine. Furthermore, pharmacological or intra-bladder uroprotection should focus on the first 8 h of CP administration.
In conclusion, the present report is the first to investigate the urinary excretion and pharmacokinetics of ACRO following CP administration. Patients who developed HC significantly excreted more ACRO in the first 8 h than did the patients who did not develop HC, whereas, the fraction of CP excreted as ACRO in 24-h urine was not significantly different. This suggests that the rate of appearance of ACRO in urine is more crucial for developing HC than the cumulative amount excreted. Further investigations with more HC patients are needed to elaborate on these findings.
